My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 482 / https://doi.org/10.3332/ecancer.2014.482

Review

Hurdles and delays in access to anti-cancer drugs in Europe

Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

Keywords: drug uptake, European Medicines Agency (EMA), European Union, marketing authorization, pricing and reimbursement, prescription and compliance

Loading Article Metrics ... Please wait

Related articles

Research: Evidence on the cost of breast cancer drugs is required for rational decision making

Abstract | Full Article | PDF Published: 16 Apr 2018 / https://doi.org/10.3332/ecancer.2018.825

Clinical Study: Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents

Abstract | Full Article | PDF Published: 11 Apr 2018 / https://doi.org/10.3332/ecancer.2018.824

Review: Risk sharing agreements, present and future

Abstract | Full Article | PDF | Portuguese Published: 10 Apr 2018 / https://doi.org/10.3332/ecancer.2018.823

Conference Report: Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt

Abstract | Full Article | PDF Published: 22 Mar 2018 / https://doi.org/10.3332/ecancer.2018.820

Conference Report: Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8–9 February 2018

Abstract | Full Article | PDF Published: 05 Mar 2018 / https://doi.org/10.3332/ecancer.2018.817



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence